Reversal of Anticoagulation in Intracranial Bleeding

Introduction to Anticoagulant Reversal

The American College of Critical Care Medicine recommends immediate discontinuation of all anticoagulants and initiation of urgent reversal therapy without waiting for laboratory confirmation, as time to reversal directly impacts mortality and hematoma expansion in anticoagulant-associated intracranial hemorrhage 1, 2

For patients with INR ≥1.4, the American Heart Association recommends administering 4-factor prothrombin complex concentrate (PCC) plus vitamin K 10 mg IV immediately, which is superior to fresh frozen plasma and achieves faster, more complete reversal 1, 3
The dosing protocol for 4-factor PCC is 25-50 IU/kg IV based on weight and INR, and vitamin K 10 mg IV should be administered slowly over 20-30 minutes, given concomitantly with PCC to prevent INR rebound 1, 2, 3

The American College of Critical Care Medicine recommends idarucizumab 5g IV as the first-line treatment for dabigatran reversal, which is the specific FDA-approved reversal agent 1, 2
For factor Xa inhibitors, the American College of Critical Care Medicine recommends andexanet alfa 5g IV (low-dose regimen) or 10g IV (high-dose regimen) based on timing and dose of last DOAC intake, as an alternative to idarucizumab 1, 2

The American College of Critical Care Medicine recommends protamine 1 mg IV for every 100 units of heparin administered in the previous 2-3 hours (maximum 50 mg single dose) for unfractionated heparin reversal 1, 2
For low molecular weight heparin (LMWH) reversal, the American College of Critical Care Medicine recommends protamine 1 mg IV per 1 mg enoxaparin (max 50 mg) if dosed within 8 hours, and 0.5 mg IV per 1 mg enoxaparin (max 50 mg) if dosed within 8-12 hours 1, 2

The American College of Critical Care Medicine recommends never delaying reversal while waiting for INR results, and initiating treatment immediately based on medication history alone 1, 3, 4
The American Heart Association recommends never using vitamin K alone without PCC or FFP, as vitamin K takes 12-24 hours to work and does not provide immediate reversal 4

The European Heart Journal recommends assessing individual risk-benefit when considering reversal in patients with concurrent symptomatic thrombosis, ischemia, heparin-induced thrombocytopenia, or DIC, but notes that the immediate mortality risk from ongoing bleeding typically outweighs thrombotic risk, and reversal should proceed 1, 2, 5
The European Heart Journal recommends resuming anticoagulation after 1 week for intracranial hemorrhage, particularly intracerebral hemorrhage, as the long-term risk of further intracranial bleeding is lower than the risk of valve thrombosis or thromboembolic events 5